The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Numis adds Virgin Money, Derwent and Northgate to 'top picks' list

Fri, 01st Apr 2016 15:34

(ShareCast News) - Numis sell-side analysts provided a list of their top picks among large and small cap stocks across the market, including ARM Holdings, Virgin Money, Derwent London, Tullow Oil, Northgate and Vectura.After another strong set of quarterly results, ARM remains the top pick as Numis believes the recent investments should be taken as a sign of confidence that historic growth rates can be sustained as ARM deepens its value add in existing markets and continues to address new markets."The analyst meeting indicated confidence in further growth in mobile despite slower growth in smartphone volumes, with growth coming from higher royalties with increased performance as with v8, multiple cores and additional IP," the broker said, with strong prospects in enterprise infrastructure and 'embedded intelligence'.The stock trades at a p/e of 28.8x, below the bottom of the 30-55x historic range, whereas prospects to sustain earnings growth at least in the high teens "continue to remain very strong".Virgin Money was added to the list on the view that it will continue to benefit from both strong earnings growth and improving return on tangible equity (ROTE) while markets remain favourable and mainstream competition is "distracted/restricted"."Furthermore, improved utilisation of the operating infrastructure acquired from Northern Rock should, in our view, underpin significant balance sheet growth for very little incremental cost." A target price of 490p is more than £1 above the current market price.Derwent London is another new addition to the top picks portfolio, replacing British Land, with the comment that its return profile evolved through FY15 with the mix of returns has shifting from yields to estimated rental value (ERV) growth.ERVs have been accelerating since early 2013, they remain some way below levels seen in 2006 but, while slowing, are thought likely to remain positive through to 2019."Rising construction capacity constraints and cost inflation increase the likelihood of delays across the broader London development pipeline but DLN has locked in construction packages and costs, in sterling-terms, on three of its four live developments, and is close to finalising the remaining package for 80 Charlotte St."While there are macro uncertainties such as the mayoral election and Brexit vote, a strong balance sheet, an attractive development pipeline and significant organic reversion off low passing rents, gives analysts confidence in their 3,850p target price.Tullow, despite being among the most shorted stocks on the FTSE, remains in the list on analysts belief that Tullow "could be ideally positioned for a future recovery in oil prices", as it is able to withstand a period of low oil prices while completing its major development project, the TEN field offshore Ghana where first oil is due in the middle of this year.On Vectura, Numis set a price target of 264p, offering around 60% updside to the current price on a 12-month view as the respiratory specialist merges with peer Skyepharma in "one of the most complementary mergers in the UK Healthcare sector", as the enlarged group has competitive advantages in both drug delivery and respiratory formulations and offers exposure to several emerging royalty streams through partnerships with Big Pharma partners."Vectura specifically benefits from Skyepharma's fast growing earnings and cash-flow, which will, in our opinion, accelerate the enlarged group's transition to being a specialist pharmaceutical company with the financial strength to commercialise novel drugs and devices in niche segments itself."House stock Northgate is another new name on the list, with a target price of 560p as the shares are felt to offer an "attractive combination of cyclical and selfhelp growth drivers, income attractions, and a valuation that reflects the historicchanges to the depreciation rates and UK operational issues, rather than the scope for further improvement".
More News
27 May 2020 13:10

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

Read more
1 May 2020 14:30

Vectura upbeat on EMA nod for 'Enerzair Breezhaler'

(Sharecast News) - Inhalation contract manufacturer Vectura Group noted an announcement from Novartis on Friday, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of 'Enerzair Breezhaler'.

Read more
23 Mar 2020 09:43

UK BROKER RATINGS SUMMARY: Barclays Raises Pearson, Moneysupermarket

UK BROKER RATINGS SUMMARY: Barclays Raises Pearson, Moneysupermarket

Read more
17 Mar 2020 12:31

Vectura Resilient Against Covid-19 As Flutiform Drives Annual Growth

Vectura Resilient Against Covid-19 As Flutiform Drives Annual Growth

Read more
10 Mar 2020 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
27 Jan 2020 09:36

UK BROKER RATINGS SUMMARY: Peel Hunt Cuts Ashtead And Raises DCC

UK BROKER RATINGS SUMMARY: Peel Hunt Cuts Ashtead And Raises DCC

Read more
21 Jan 2020 12:48

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Read more
13 Jan 2020 09:19

Vectura Targeting New Royalties In 2020 As Glaxo Lawsuit Rumbles On

Vectura Targeting New Royalties In 2020 As Glaxo Lawsuit Rumbles On

Read more
13 Jan 2020 08:25

Vectura sees FY revenues and earnings 'at least' in line with expectations

(Sharecast News) - Pharmaceuticals company Vectura said on Monday that its base business had continued to perform well in 2019.

Read more
27 Nov 2019 08:26

TOP NEWS: Hikma Submits Response To Advair Application Deficiencies

TOP NEWS: Hikma Submits Response To Advair Application Deficiencies

Read more
29 Oct 2019 09:41

Vectura Group Hires Former GE Healthcare Exec Will Downie As New CEO

Vectura Group Hires Former GE Healthcare Exec Will Downie As New CEO

Read more
18 Oct 2019 16:06

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
4 Oct 2019 17:31

UPDATE 1-Vectura, Sandoz win ruling on inhaler packaging case against GSK

(Adds comment from GSK spokesman)Oct 4 (Reuters) - Vectura Group said on Friday a British court had ruled in its favour on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.Vectura said the court dismissed all G...

Read more
4 Oct 2019 14:24

High Court Dismisses Glaxo Case Against Generic Seretide Accuhaler

High Court Dismisses Glaxo Case Against Generic Seretide Accuhaler

Read more
3 Oct 2019 16:04

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.